Alcohol is consumed by approximately 2.3 billion adults around the world. 1 In 2017, approximately 86% of US adults reported drinking any alcohol during their lifetime, 70% reported drinking in the past year, and 60% reported drinking in the past month. 2 The adverse health consequences of excessive alcohol intake are clear, 3 yet many adults also consume alcohol at low to moderate levels, where the risk for adverse outcomes is less evident. An estimated 17.9 million people died from cardiovascular diseases (CVD) in 2016, making it the leading cause of death worldwide. 4 Alcohol may, or may not, have benefits on CVD risk. Thus, understanding the relationship between alcohol consumption and risk for CVD morbidity and mortality is of great importance to public health.
More than 100 observational epidemiologic studies have reported associations of health benefits from moderate consumption compared with abstinence, including lower risk of obesity, 5,6 better cardiorespiratory fitness, 7 type II diabetes, 8, 9 CVD, 10-12 and mortality. 13 Furthermore, the current Dietary Guidelines Advisory Committee identified that moderate alcohol intake can be a component of a healthy dietary pattern. 14 However, caution was given about initiating drinking to gain health benefits given concerns about potential increased risk of violence, drowning, unintentional injuries, and increased risk of breast cancer in women. By design, observational studies limit our ability to draw causal inferences about alcohol and health outcomes. For example, individuals who abstain from alcohol may differ in important ways from those who use alcohol moderately, and these differences may confound the results of observational associations, as these differences may be difficult to fully capture and account for in observational studies. Like heavy alcohol use, it is possible that moderate alcohol use may also increase the risk of driving and using heavy machinery, may increase the risk of certain cancers, 15, 16 and may contribute to alcohol abuse disorders. 3, 17 Consequently, moderate alcohol use is widespread worldwide, but neither its potential benefits nor its potential harms are fully understood. Due to the inherent limitations of observational studies, addressing this critical public health problem definitively will require carefully designed clinical trials.
The Moderate Alcohol and Cardiovascular Health Trial (MACH15) was designed to evaluate the effects of moderate alcohol use versus abstention on cardiovascular outcomes. The trial was supported and approved by the National Institute on Alcohol Abuse and Alcoholism, and was designed to recruit 7800 individuals with moderate to high CVD risk who would be followed over an average of six years. Specifically, the two-arm open-label clinical trial aimed to enroll participants aged 50 years and older, who were neither abstinent of alcohol nor consumed more than one serving of an alcoholic beverage (11-15 g/day) daily. Seven vanguard centers across the world had initiated recruitment when the study was abruptly terminated. The investigators describe their design and initial trial experience in this issue of the journal.
The MACH15 investigators should be congratulated for their careful efforts to address both the risks and benefits of moderate alcohol exposure to the potential study participants. Strengths of the study design included allowing participants the opportunity to choose the type of alcohol they would consume to address individual preferences and improve adherence; allowing eight ''day-off'' passes during each year to allow alcohol consumption among those assigned to the abstention arm, and brief abstention among those assigned to the moderate drinking arm, and randomizing family members in the same household to the same study arm in an effort to maximize protocol adherence. Additional design elements such as counseling and motivational interviewing methods were enacted, and biomarker monitoring was to be used to reduce social desirability bias and enhance separation of the two trial arms. Another important strength was the decision to enroll participants at high risk for CVD events, which not only lowered the sample size needed to detect the primary endpoint, but also the number of participants exposed to risks inherent to the trial.
Despite its many strengths, the trial also had some limitations. First, the investigators' decision to distribute compensation as a gift/debit card for alcoholic beverages at some centers could have presented challenges, including the inability to track specific usage for the purchase of alcoholic beverages, and potentially allowing the opportunity to use study funds for items available at grocery or liquor stores other than alcohol. In addition, the estimated event rates used to calculate the sample size were based primarily on the Systolic Blood Pressure Intervention Trial (SPRINT) from the US; however, the study was designed to recruit participants from the Netherlands, Nigeria, Argentina, Denmark, and Spain, among others, and CVD event rates may differ among these regions. Although measures to ensure adherence were considered carefully, noncompliance and, more specifically, the potential for cross-over from the abstinence arm to the moderate drinking arm was perhaps the biggest threat to the success of the MACH15 trial. The degree to which cross-overs substantially decrease statistical power is not widely appreciated, and this can attenuate the expected difference between trial arms and inflate the sample size by the square of that factor. 18 Because both study arms were already consuming low to moderate levels of alcohol before the start of the trial, and because ''day off'' passes were built into the design, the possibility of substantial cross-overs, lack of sufficient separation across arms, and the expensive price paid in statistical power was certainly present.
Given the widespread use of alcohol, the high risk of CVD as a cause of morbidity and mortality worldwide, and uncertain health benefits and risks of moderate alcohol consumption, MACH15 was poised to make extremely important contributions to public health. Decades of additional observational data would not nearly move the field forward as much as this trial, so long as adherence and separation across arms was achieved. Although the trial had some design limitations, as all trials do, overall, the sound methods and careful design are exemplary, and provide guidance to how similar trials might be designed and implemented if future opportunities to study moderate alcohol manifest. The unfortunate early termination of MACH15 is a missed opportunity, as we will continue to base public health advice on observational studies that are likely biased, until similar trials are conducted at some indeterminate future time.
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